ImmunityBio Resubmits ANKTIVA Application, Pursues Enhanced Cancer Treatment Data

ImmunityBio Advances Cancer Therapy Application Amid Calls for More Data

ImmunityBio, a pivotal player in the immunotherapy sector based in Culver City, California, makes significant strides in addressing bladder cancer treatment. The company has recently resubmitted its supplemental Biologics License Application (sBLA) for ANKTIVA® (nogapendekin alfa inbakicept-pmln), aimed at treating BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) with papillary tumors. Engaging in detailed discussions with the U.S. Food and Drug Administration (FDA) since January 2026, the company responds to the FDA's requests for additional supportive data. This process involves submitting a follow-up in February 2026, after which feedback received in March calls for updated efficacy information, marking a crucial phase in the drug's approval journey.

Dr. Patrick Soon-Shiong, Founder and Executive Chairman of ImmunityBio, underlines the company's dedication to fulfilling the medical needs of the approximately 60,000 patients diagnosed annually with NMIBC in the United States, especially considering that about 70% of these cases involve papillary (Ta) disease. Dr. Soon-Shiong emphasizes the importance of the long-term safety and efficacy data regarding ANKTIVA plus BCG, as highlighted in reputable scientific publications. Findings from such studies illuminate the potential of interleukin-15 (IL-15), identified by esteemed organizations as a promising molecule in advancing cancer therapy. The resubmission of ANKTIVA not only builds on its previously established efficacy—having been approved in 2024 for NMIBC with carcinoma in situ—but also represents a vital step towards meeting the unmet medical needs within this patient demographic.

As ImmunityBio maneuvers through the complexities of regulatory approvals, the focus remains steadfast on enhancing bladder preservation and promoting disease-free survival among NMIBC patients. The commitment to advancing ANKTIVA underlines the strategic intent to provide novel therapeutic options for this challenging cancer landscape, demonstrating ImmunityBio’s broader mission in improving treatment outcomes through innovation. The update marks a renewed effort in positioning ANKTIVA as a foundational option for patients facing limited treatment alternatives, consequently reinforcing ImmunityBio's role in the immunotherapy domain.

In related news, ImmunityBio's recent stock market performance reflects broader investor sentiments, though the specifics regarding any share price changes remain undisclosed. Despite the market’s fluctuations, the company's ongoing developments—including clinical trials and potential partnerships—may play a crucial role in shaping future investor confidence. As ImmunityBio continues its pursuit of groundbreaking therapies, the dynamic nature of biopharmaceuticals remains evident, showcasing both challenges and opportunities for the company.